|
Table 2: Small vessel disease trials. |
|||||
|
Trial |
Design |
Year |
n |
Scenario |
Material |
|
BASKET 256 |
1:1, Open-Label, Core Lab, CEC |
2018 |
758 |
Small vessel |
EES, PES, PCB 3 µg/mm2 iopromide |
|
BELLO57 |
1:1, Open-Label, Core Lab, CEC |
2012 |
182 |
Small vessel |
BMS, PES |
|
PEPCAD58 |
Open-Label, Core Lab, CEC |
2010 |
118 |
Small vessel |
PCB 3 µg/mm2 iopromide, BMS bailout |
|
PICCOLETO59 |
1:1, Open-Label, CEC |
2010 |
57 |
Small vessel |
PES, PCB 3 µg/mm2 PTX DMSO (d(i)m(ethyl)s(ulf)o(xide) |
|
PICCOLETO II60 |
1:1, Open-Label, CEC |
2020 |
214 |
Small vessel |
EES, PCB ≈2 µg/mm2 |
|
RESTORE61 |
1:1, Open-Label, Core Lab, CEC |
2018 |
230 |
Small vessel |
EES, PCB 3 µg/mm2 iopromide |
|
CEC = clinical events committee. EES = everolimus-eluting stent. PES = paclitaxel-eluting stent. PCB = paclitaxel-coated balloon. BMS = bare metal stent. PTX DMSO = paclitaxel dimethyl sulfoxide. |
|||||